Sharon Sakai
General Counsel bei TEMPEST THERAPEUTICS, INC.
Profil
Sharon Sakai is currently the Head-Regulatory & Quality at Tempest Therapeutics, Inc. Previously, she held the position of Vice President-Regulatory & Quality at Transcept Pharmaceuticals, Inc. (Old) from 2005 to 2013.
She also worked as a Member at Peninsula Pharmaceuticals, Inc. Dr. Sakai served as the Vice President-Regulatory Affairs at Adamas Pharmaceuticals LLC from 2013 to 2015.
Additionally, she was a Member at Onyx SAS and Vice President-Regulatory Affairs at Transcept Pharma, Inc. Dr. Sakai completed her undergraduate degree at Cornell University and obtained a doctorate from the University of California, Berkeley.
Aktive Positionen von Sharon Sakai
| Unternehmen | Position | Beginn |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | General Counsel | - |
Ehemalige bekannte Positionen von Sharon Sakai
| Unternehmen | Position | Ende |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | General Counsel | 01.01.2015 |
Transcept Pharmaceuticals, Inc. (Old)
 Transcept Pharmaceuticals, Inc. (Old) Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA. | General Counsel | 01.06.2013 |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | General Counsel | - |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Corporate Officer/Principal | - |
Onyx SAS
 Onyx SAS Environmental ServicesIndustrial Services Onyx provides energy, water purification and distribution, waste management, and construction services. The company is headquartered in Bron, France. | Corporate Officer/Principal | - |
Ausbildung von Sharon Sakai
| Cornell University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Transcept Pharmaceuticals, Inc. (Old)
Transcept Pharmaceuticals, Inc. (Old) Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA. | Health Technology |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Onyx SAS
Onyx SAS Environmental ServicesIndustrial Services Onyx provides energy, water purification and distribution, waste management, and construction services. The company is headquartered in Bron, France. | Industrial Services |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
